TITLE

Successful osimertinib rechallenge in a patient with advanced non-small cell lung cancer following osimertinib-induced interstitial lung disease after treatment with nivolumab

AUTHOR(S)
Mamesaya, Nobuaki; Kenmotsu, Hirotsugu; Takahashi, Toshiaki
PUB. DATE
December 2017
SOURCE
Investigational New Drugs;Dec2017, Vol. 35 Issue 6, p839
SOURCE TYPE
Academic Journal
DOC. TYPE
Report
ABSTRACT
No abstract available.
ACCESSION #
126307968

 

Related Articles

  • Change in serum KL-6 level from baseline is useful for predicting life-threatening EGFR-TKIs induced interstitial lung disease. Kawase, Shigeo; Hattori, Noboru; Ishikawa, Nobuhisa; Horimasu, Yasushi; Fujitaka, Kazunori; Furonaka, Osamu; Isobe, Takeshi; Miyoshi, Seigo; Hamada, Hironobu; Yamane, Takashi; Yokoyama, Akihito; Kohno, Nobuoki // Respiratory Research;Jul2011, Vol. 12 Issue 7, p1 

    Background: A high incidence of interstitial lung disease (ILD) has been reported in patients with advanced non-small cell lung cancer (NSCLC) treated with epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), particularly in Japanese populations. A previous...

  • Proteomic Biomarkers for Acute Interstitial Lung Disease in Gefitinib-Treated Japanese Lung Cancer Patients. Nyberg, Fredrik; Ogiwara, Atsushi; Harbron, Chris G.; Kawakami, Takao; Nagasaka, Keiko; Takami, Sachiko; Wada, Kazuya; Tu, Hsiao-Kun; Otsuji, Makiko; Kyono, Yutaka; Dobashi, Tae; Komatsu, Yasuhiko; Kihara, Makoto; Akimoto, Shingo; Peers, Ian S.; South, Marie C.; Higenbottam, Tim; Fukuoka, Masahiro; Nakata, Koichiro; Ohe, Yuichiro // PLoS ONE;2011, Vol. 6 Issue 7, p1 

    Interstitial lung disease (ILD) events have been reported in Japanese non-small-cell lung cancer (NSCLC) patients receiving EGFR tyrosine kinase inhibitors. We investigated proteomic biomarkers for mechanistic insights and improved prediction of ILD. Blood plasma was collected from 43...

  • Role of Tyrosine Kinase Inhibitors in Lung Cancer. Ansari, J.; Palmer, D. H.; Rea, D. W.; Hussain, S. A. // Anti-Cancer Agents in Medicinal Chemistry;2009, Vol. 9 Issue 5, p569 

    Protein tyrosine kinases are enzymes which catalyze the phosphorylation of tyrosine residues and activate a downstream cascade of cellular signalling pathways which regulate cell proliferation, differentiation and apoptosis and a wide variety of cellular functions. Clinical developments over the...

  • Research Progress of HGF/c-MET Inhibitor in the Treatment of Non-small Cell Lung Cancer. Tao JIANG; Caicun ZHOU // Chinese Journal of Lung Cancer;4/20/2015, Vol. 18 Issue 4, p240 

    Molecular targeted therapy has become more and more important in the treatment of non-small cell lung cancer (NSCLC). HGF/c-MET plays the pivotal role in the growth, development and tolerance to epidermal growth factor receptor tyrosine kinase inhibitor of NSCLC. Moreover it has become another...

  • Gefitinib in Patients of Asian Ethnicity or Never Smokers. Toschi, Luca; Cappuzzo, Federico // Asia Pacific Journal of Oncology & Hematology;2009, Vol. 1 Issue 1, p45 

    Gefitinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, has been proven to be active in selected patients with advanced non-small cell lung cancer (NSCLC), including women, patients with adenocarcinomas, Asians and never smokers. The biological reasons underlying this...

  • The Role of Pemetrexed in Lung Adenocarcinoma, Mixed Subtype with Bronchioloalveolar Carcinoma Features. Duruisseaux, Micha�l; Cadranel, Jacques; P�rol, Maurice; Arpin, Dominique // Current Drug Targets;Jan2010, Vol. 11 Issue 1, p74 

    No abstract available.

  • Intercalation of Erlotinib and Pemetrexed in the Treatment of Non-Small Cell Lung Cancer. Tianhong Li; Lara Jr., Primo N.; Mack, Philip C.; Perez-Soler, Roman; Gandara, David R. // Current Drug Targets;Jan2010, Vol. 11 Issue 1, p85 

    No abstract available.

  • Second-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer. Sequist, Lecia V. // Oncologist;Mar2007, Vol. 12 Issue 3, p325 

    Inhibiting epidermal growth factor receptor (EGFR) signaling has proven to be an effective strategy for treating non-small cell lung cancer (NSCLC) patients and the first generation of agents developed for this purpose, gefitinib and erlotinib, stimulated a unique escalation in both biologic and...

  • Impact of EGFR mutations on treatment of non-small cell lung cancer. Johnson, Bruce E.; Jackman, David; Jänne, Pasi A. // Cancer Chemotherapy & Pharmacology. Supplement;Dec2006, Vol. 58, p5 

    Somatic mutations in the epidermal growth factor receptor ( EGFR) have been identified in advanced non-small cell lung cancer (NSCLC) patients who achieve dramatic clinical and radiographic responses to treatment with the EGFR tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib....

  • Current Roles and Future Perspectives of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Advanced Non-Small-Cell Lung Cancer. Lin, Zhong-Zhe; Yang, Chih-Hsin // European Journal of Clinical & Medical Oncology;2010, Vol. 2 Issue 3, p1 

    Clinical application of first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib has revolutionized systemic treatment for advanced non-small-cell lung cancer (NSCLC) patients. The therapeutic efficacy of EGFR-TKI monotherapy as a...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics